Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Recruiting

Phase 3

Rina-S vs. Investigator's ChoiceStudy to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Sponsor:

Genmab

Code:

NCT06619236

Conditions

Platinum-resistant Ovarian Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Rina-S

Paclitaxel

Topotecan

Pegylated liposomal doxorubicin (PLD)

Gemcitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-02. This information was provided to ClinicalTrials.gov by Genmab on 2025-06-05.